Pervasis has developed cell-based therapies that induce repair and regeneration in a wide array of tissues. The company’s lead products are based on our proprietary allogeneic endothelial cell technology, shown in preclinical studies to restore vascular function after injury and disruption. Their flagship product, Vascugel®, is designed to treat vascular injury in a number of clinical settings, to include, yet not limited to vascular access, coronary bypass graft, limb salvage, and peripheral bypass failure.

Flagship Managing Partner Ed Kania is on the Board of Directors.

www.pervasistx.com